There is 1 paper on P21 immunopositivity in aging research: none in people yet, 1 in animals.
1 paper studies it4 findings
- Animals1
Effects
1Age
no changein dogs1
1 study
Age
no changein dogs1
P21 immunopositivity showed no clear effect on age in dogs with chronic hepatitis (above 70% in 23/26 cases).
“exceeded 70% in 23/26 cases with no association with age”
Animalsin dogs with chronic hepatitislivern = 26
Journal of veterinary internal medicine
Upstream
1Chronic hepatitis
upin dogs1
1 study
Chronic hepatitis
upin dogs1
Chronic hepatitis increases P21 immunopositivity in dogs (compared with control dogs with normal liver histology) (median 90% positive hepatocytes (range 20%-98%)).
“Hepatocyte p21 immunopositivity in dogs with CH was high (median percentage of positive hepatocytes: 90%, range: 20%-98%)”
Animalscompared with control dogs with normal liver histologylivern = 26
Journal of veterinary internal medicine
Associations
2Survival time
downin dogs1HR 4.12
1 study
Survival time
downin dogs1HR 4.12
P21 immunopositivity predicts survival time in dogs with chronic hepatitis (HR 4.12; 95% CI 1.34-12.63; 218 versus 874 days for upper versus lowest tercile, P = .006).
“Increasing hepatocyte p21 immunopositivity was significantly negatively associated with survival time (HR 4.12; 95% CI 1.34-12.63; P = .013).”
Animalsin dogs with chronic hepatitislivern = 26
Journal of veterinary internal medicine
Age
upin dogs1
1 study
Age
upin dogs1
P21 immunopositivity is associated with age in control dogs with normal liver histology (rs = 0.63; P = .011).
“was positively correlated with age (rs = 0.63; P = .011)”
Animalsin control dogs with normal liver histologylivern = 15
Journal of veterinary internal medicine